|Bid||101.55 x 800|
|Ask||103.80 x 1000|
|Day's Range||101.75 - 102.70|
|52 Week Range||68.93 - 106.51|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||18.39|
|Earnings Date||Oct 19, 2021|
|Forward Dividend & Yield||4.80 (4.83%)|
|Ex-Dividend Date||Jun 24, 2021|
|1y Target Est||109.57|
Johnson & Johnson (NYSE: JNJ) and Philip Morris International (NYSE: PM) are two such reliable dividend payers. At $435 billion (by market capitalization), healthcare titan Johnson & Johnson is a favorite of many dividend investors for several reasons. The pharmaceutical segment is led by immunology drugs such as Stelara and Tremfya, and cancer drugs such as Darzalex and Imbruvica (which is co-owned by Johnson & Johnson and AbbVie).
Microsoft plans to boost its quarterly payout by 6 cents, or 11%, to 62 cents a share from 56 cents.
Philip Morris, the maker of Marlboros, has bought an asthma inhaler manufacturer, as part of its effort to turn itself into a pharma company. Healthcare advocates don't like it.